CVRx, Inc. (CVRX)
NASDAQ: CVRX · Real-Time Price · USD
7.83
-0.54 (-6.45%)
At close: Apr 8, 2026, 4:00 PM EDT
7.88
+0.05 (0.64%)
After-hours: Apr 8, 2026, 4:11 PM EDT
CVRx, Inc. Employees
CVRx, Inc. had 223 employees as of December 31, 2025. The number of employees increased by 17 or 8.25% compared to the previous year.
Employees
223
Change (1Y)
17
Growth (1Y)
8.25%
Revenue / Employee
$254,040
Profits / Employee
-$239,040
Market Cap
206.02M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 223 | 17 | 8.25% |
| Dec 31, 2024 | 206 | 6 | 3.00% |
| Dec 31, 2023 | 200 | 40 | 25.00% |
| Dec 31, 2022 | 160 | 51 | 46.79% |
| Dec 31, 2021 | 109 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inogen | 753 |
| InfuSystem Holdings | 473 |
| RxSight | 461 |
| Sight Sciences | 186 |
| Electromed | 180 |
| 908 Devices | 172 |
| ClearPoint Neuro | 172 |
| Profound Medical | 162 |
CVRX News
- 5 weeks ago - CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 - GlobeNewsWire
- 2 months ago - CVRx Kicks Off One Of The Largest Heart Device Trials In History - Benzinga
- 2 months ago - CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population - GlobeNewsWire
- 3 months ago - CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance - GlobeNewsWire
- 3 months ago - CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy - GlobeNewsWire
- 3 months ago - CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 months ago - CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire